Vosaroxin

N/A

Report date: 2024/10/28 20:00:51
NME

Base Information

Drug NameVosaroxin
Drug Alias Namevosaroxine伏利拉辛vosaroxina沃沙洛星vosaroxinum +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTopoisomerase II inhibitors
TargetsTopoisomerase II
Therapy Area/IndicationsSolid tumoursAcute DiseaseMyelodysplastic Syndromes +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[17] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSumitomo Dainippon
China Registration ClassN/A

Develop Information

Active CompaniesXoma CorpWashington University School Of MedicineDenovo Biopharma Llc +[4] 
Inactive CompaniesWeill Medical College of Cornell UniversityCardiff UniversitySunesis Pharmaceuticals Inc +[5] 
Active IndicationsSolid tumoursMyelodysplastic SyndromesSarcoma, Myeloid +[5] 
Inactive IndicationsAcute DiseaseSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[8] 

Other Information

ATC CodeL01XX53
Related LinksWikipediaKEGG